Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Sales & Marketing
Aktiia company profile
Sponsored

Company Profile: Aktiia

Hypertension is known to be one of the most prevalent chronic health conditions globally.

R&D
Veeva R&D and Quality 2024 - Chris Moore

Veeva R&D and Quality 2024: Chris Moore

During the Veeva R&D and Quality Summit held in Madrid last month, web editor Nicole Raleigh sat down with Chris Moore, president of Europe for Veeva Systems, to discuss the event and i

Sales & Marketing

Digital

Market Access

Market Access
Mumbai, India

What India can learn from Kinvard Bio

India needs its own version of pull, designed for an Indian payer mix, an Indian procurement structure, and an Indian distributor network.

Editor's Picks

  1. Revolution's ASCO showstopper gets FDA greenlight
  2. Anthropic AI tool conducts physical scientific experiments
  3. UK MHRA authorises orforglipron private prescription
  4. Roche’s Genentech strikes $2.3bn deal for Hanmi obesity drug HM17321
  5. Sword Health buys Headspace in $200m to $300m deal

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

more

Patients

more

R&D

more